Tolka AI Therapeutics
Tolka AI Therapeutics is a biotechnology company pioneering phage therapy to combat antibiotic-resistant infections, specifically targeting Mycobacterium abscessus complex pulmonary disease (MABC-PD). The company develops safe, effective, patient-tailored bacteriophage therapies using advanced AI and machine learning technologies to overcome antibiotic resistance and microbiome dysbiosis. Their platform includes a pipeline for phage therapy development, proprietary technology for generating superphages and optimizing phage cocktails, and an expanded access program for physicians treating MABC-PD. Tolka AI Therapeutics combines expertise in microbiology, bioinformatics, and software engineering to deliver innovative treatments for chronic, hard-to-treat infections, positioning itself as a leader in the precision medicine and antimicrobial resistance space.
Tolka AI Therapeutics
Tolka AI Therapeutics is a biotechnology company pioneering phage therapy to combat antibiotic-resistant infections, specifically targeting Mycobacterium abscessus complex pulmonary disease (MABC-PD). The company develops safe, effective, patient-tailored bacteriophage therapies using advanced AI and machine learning technologies to overcome antibiotic resistance and microbiome dysbiosis. Their platform includes a pipeline for phage therapy development, proprietary technology for generating superphages and optimizing phage cocktails, and an expanded access program for physicians treating MABC-PD. Tolka AI Therapeutics combines expertise in microbiology, bioinformatics, and software engineering to deliver innovative treatments for chronic, hard-to-treat infections, positioning itself as a leader in the precision medicine and antimicrobial resistance space.